Sparsentan

Sparsentan
Clinical data
Trade names	Filspari
Other names	RE-021, PS433540
AHFS/Drugs.com	Monograph
MedlinePlus	a623018
License data	US DailyMed: Sparsentan;
Pregnancy; category	Contraindicated;
Routes of; administration	By mouth
ATC code	C09XX01 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	254740-64-2;
PubChem CID	10257882;
DrugBank	DB12548;
UNII	9242RO5URM;
KEGG	D11776;
ChEBI	CHEBI:229526;
ECHA InfoCard	100.275.317
Chemical and physical data
3D model (JSmol)	Interactive image;
	SMILES CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C(COCC)=C1)C1=CC=CC=C1S(=O)(=O)NC1=NOC(C)=C1C;
	InChI InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35); Key:WRFHGDPIDHPWIQ-UHFFFAOYSA-N;

Sparsentan, sold under the brand name Filspari, is a medication used for the treatment of primary immunoglobulin A nephropathy. Sparsentan is an endothelin and angiotensin II receptor antagonist. It is taken by mouth.

The most common side effects include swelling of the extremities, low blood pressure, dizziness, high blood potassium, anemia, injury to the kidney, and increased liver enzymes in the blood.

It was approved for medical use in the United States in February 2023. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.